What is Arcutis Biotherapeutics, Inc.'s unrealized gains?

Arcutis Biotherapeutics, Inc. (ARQT) reported unrealized gains of $0 in Q1 2026.

What is the long-term trend for Arcutis Biotherapeutics, Inc.'s unrealized gains?

Over 2 years (2023 to 2025), Arcutis Biotherapeutics, Inc.'s unrealized gains has grown at a -100.0% compound annual growth rate (CAGR), from $3K to $0.

Arcutis Biotherapeutics, Inc. ARQT Unrealized gains

Other financials

Income statement

See full

Revenue$105.4M+60.1%

Gross profit$95.6M+67.7%

Operating income-$9.1M+62.9%

Net income-$11.3M+54.9%

EPS (diluted)-$0.09+55.0%

Balance sheet

See full

Cash & equivalents$35.1M-34.7%

Total debt$114.7M+3.5%

Total equity$189.6M+32.9%

Total assets$460.0M+33.7%

Cash flow

See full

Operating cash flow$2.2M+107%

CapEx--100%

Free cash flow$2.2M+107%

Valuation

See full

Market cap$3.29B+57.5%

Profitability

See full

Gross margin90.9%+2.5pp

Operating margin-12%-5.7pp

Net margin-13.9%-6.6pp

FCF margin-52.5%-21.9pp

Returns & leverage

See full

Return on equity-28.2%-13.0pp

Debt / equity0.6×-0.2×

Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept arqt:CashAndCashEquivalentsUnrealizedGain.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s unrealized gains?: Arcutis Biotherapeutics, Inc. (ARQT) reported unrealized gains of $0 in Q1 2026.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s unrealized gains?: Over 2 years (2023 to 2025), Arcutis Biotherapeutics, Inc.'s unrealized gains has grown at a -100.0% compound annual growth rate (CAGR), from $3K to $0.